Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment

Table 3 Risk factors associated with the risk of hepatocellular carcinoma development

	Univariate analysis, OR (95% CI)	P value	Multivariate analysis, OR (95% CI)	P value
Age (per yr increase)	1.1 (1.0-1.1)	< 0.001	1.1 (1.0-1.1)	< 0.001
Gender (male vs female)	7.2 (1.7-30.6)	0.004	8.9 (1.1-70.7)	0.038
Platelet1 (103/mL)	1.0 (1.0-1.0)	< 0.001	1.0 (1.0-1.0)	< 0.001
AFP (ng/mL)	1.0 (1.0-1.0)	< 0.001	1.0 (1.0-1.0)	0.141
HBeAg status (positive vs negative)	1.0 (0.4-2.5)	1.000
Diabetes mellitus (yes vs no)	2.7 (1.1-6.3)	0.043	0.6 (0.2-1.7)	0.308
NA(s) before ETV/TDF (yes vs no)	2.0 (0.9-4.5)	0.143
Cirrhosis1 (yes vs no)	6.3 (2.8-14.2)	< 0.001	3.1 (1.1-8.2)	0.026
Antiviral treatment (ETV vs TDF)	0.8 (0.3-1.7)	0.642
MVR (no vs yes)	0.6 (0.2-1.4)	0.253
ALT normalization at month 6 (no vs yes)	0.4 (0.2-0.9)	0.043	0.2 (0.1-0.7)	0.009
ALT normalization at month 12 (no vs yes)	0.4 (0.2-1.0)	0.101
Virological response at month 6 (no vs yes)	0.8 (0.3-1.9)	0.622
Virological response at month 6 (no vs yes)	0.7 (0.2-2.2)	0.530

¹Cirrhosis and platelet count were analyzed separately among with other independent variables in logistic regression model as they showed collinearity.

AFP: Alpha-fetoprotein; HBeAg: Hepatitis B e antigen; CI: Confidence interval; ETV: Entecavir; MVR: Maintained virological response; NA(s): Nucleos(t)ide analogue(s); TDF: Tenofovir disoproxil fumarate.